A

Amneal Intermediate Inc
NASDAQ:AMRX

Watchlist Manager
Amneal Intermediate Inc
NASDAQ:AMRX
Watchlist
Price: 8.46 USD -2.76% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Amneal Intermediate Inc?
Write Note

Intrinsic Value

The intrinsic value of one AMRX stock under the Base Case scenario is 14.64 USD. Compared to the current market price of 8.46 USD, Amneal Intermediate Inc is Undervalued by 42%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AMRX Intrinsic Value
14.64 USD
Undervaluation 42%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Amneal Intermediate Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AMRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AMRX?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Amneal Intermediate Inc

Provide an overview of the primary business activities
of Amneal Intermediate Inc.

What unique competitive advantages
does Amneal Intermediate Inc hold over its rivals?

What risks and challenges
does Amneal Intermediate Inc face in the near future?

Has there been any significant insider trading activity
in Amneal Intermediate Inc recently?

Summarize the latest earnings call
of Amneal Intermediate Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Amneal Intermediate Inc.

Provide P/S
for Amneal Intermediate Inc.

Provide P/E
for Amneal Intermediate Inc.

Provide P/OCF
for Amneal Intermediate Inc.

Provide P/FCFE
for Amneal Intermediate Inc.

Provide P/B
for Amneal Intermediate Inc.

Provide EV/S
for Amneal Intermediate Inc.

Provide EV/GP
for Amneal Intermediate Inc.

Provide EV/EBITDA
for Amneal Intermediate Inc.

Provide EV/EBIT
for Amneal Intermediate Inc.

Provide EV/OCF
for Amneal Intermediate Inc.

Provide EV/FCFF
for Amneal Intermediate Inc.

Provide EV/IC
for Amneal Intermediate Inc.

Show me price targets
for Amneal Intermediate Inc made by professional analysts.

What are the Revenue projections
for Amneal Intermediate Inc?

How accurate were the past Revenue estimates
for Amneal Intermediate Inc?

What are the Net Income projections
for Amneal Intermediate Inc?

How accurate were the past Net Income estimates
for Amneal Intermediate Inc?

What are the EPS projections
for Amneal Intermediate Inc?

How accurate were the past EPS estimates
for Amneal Intermediate Inc?

What are the EBIT projections
for Amneal Intermediate Inc?

How accurate were the past EBIT estimates
for Amneal Intermediate Inc?

Compare the revenue forecasts
for Amneal Intermediate Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Amneal Intermediate Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Amneal Intermediate Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Amneal Intermediate Inc compared to its peers.

Compare the P/E ratios
of Amneal Intermediate Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Amneal Intermediate Inc with its peers.

Analyze the financial leverage
of Amneal Intermediate Inc compared to its main competitors.

Show all profitability ratios
for Amneal Intermediate Inc.

Provide ROE
for Amneal Intermediate Inc.

Provide ROA
for Amneal Intermediate Inc.

Provide ROIC
for Amneal Intermediate Inc.

Provide ROCE
for Amneal Intermediate Inc.

Provide Gross Margin
for Amneal Intermediate Inc.

Provide Operating Margin
for Amneal Intermediate Inc.

Provide Net Margin
for Amneal Intermediate Inc.

Provide FCF Margin
for Amneal Intermediate Inc.

Show all solvency ratios
for Amneal Intermediate Inc.

Provide D/E Ratio
for Amneal Intermediate Inc.

Provide D/A Ratio
for Amneal Intermediate Inc.

Provide Interest Coverage Ratio
for Amneal Intermediate Inc.

Provide Altman Z-Score Ratio
for Amneal Intermediate Inc.

Provide Quick Ratio
for Amneal Intermediate Inc.

Provide Current Ratio
for Amneal Intermediate Inc.

Provide Cash Ratio
for Amneal Intermediate Inc.

What is the historical Revenue growth
over the last 5 years for Amneal Intermediate Inc?

What is the historical Net Income growth
over the last 5 years for Amneal Intermediate Inc?

What is the current Free Cash Flow
of Amneal Intermediate Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Amneal Intermediate Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amneal Intermediate Inc

Current Assets 1.4B
Cash & Short-Term Investments 91.5m
Receivables 645.7m
Other Current Assets 640.7m
Non-Current Assets 2.1B
PP&E 550.1m
Intangibles 1.5B
Other Non-Current Assets 55.5m
Current Liabilities 846.6m
Accounts Payable 143.6m
Accrued Liabilities 403.1m
Short-Term Debt 179m
Other Current Liabilities 120.9m
Non-Current Liabilities 2.6B
Long-Term Debt 2.5B
Other Non-Current Liabilities 120.2m
Efficiency

Earnings Waterfall
Amneal Intermediate Inc

Revenue
2.4B USD
Cost of Revenue
-1.5B USD
Gross Profit
856.7m USD
Operating Expenses
-581.8m USD
Operating Income
274.8m USD
Other Expenses
-358.8m USD
Net Income
-84m USD

Free Cash Flow Analysis
Amneal Intermediate Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Amneal Pharmaceuticals reported strong growth in Q2 2024, with revenues rising 17% to $702 million, driven by generics and specialty medicines. The company’s 2024 revenue guidance was increased to $2.7 - $2.8 billion, reflecting a 13% to 17% year-over-year growth. Amneal is also launching CREXONT for Parkinson's disease, expected to contribute $300-$500 million in U.S. peak sales, aiding their specialty segment to exceed $500 million in revenue by 2027. Additionally, the company continues to expand its biosimilars portfolio, anticipating over $125 million in 2024 revenue from this segment.

What is Earnings Call?
Fundamental Scores

AMRX Profitability Score
Profitability Due Diligence

Amneal Intermediate Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
42/100
Profitability
Score

Amneal Intermediate Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

AMRX Solvency Score
Solvency Due Diligence

Amneal Intermediate Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
Positive Net Debt
22/100
Solvency
Score

Amneal Intermediate Inc's solvency score is 22/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMRX Price Targets Summary
Amneal Intermediate Inc

Wall Street analysts forecast AMRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMRX is 9.86 USD with a low forecast of 9.09 USD and a high forecast of 10.5 USD.

Lowest
Price Target
9.09 USD
7% Upside
Average
Price Target
9.86 USD
17% Upside
Highest
Price Target
10.5 USD
24% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AMRX?

Click here to dive deeper.

Dividends

Amneal Intermediate Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AMRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AMRX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Amneal Intermediate Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

2.6B USD

Dividend Yield

0%

Description

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 7,600 full-time employees. The company went IPO on 2009-03-16. The firm specializes in developing, manufacturing, marketing and distributing generic, injectables, biosimilars and branded specialty pharmaceutical products. Its segments include Generics, Specialty, and AvKARE. Its Generics segment includes approximately 250 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system (CNS) disorders, including Parkinson’s disease, and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Contact

NEW JERSEY
Bridgewater
400 Crossing Blvd Fl 3
+19089473120
www.amneal.com

IPO

2009-03-16

Employees

7 600

Officers

See Also

Discover More
What is the Intrinsic Value of one AMRX stock?

The intrinsic value of one AMRX stock under the Base Case scenario is 14.64 USD.

Is AMRX stock undervalued or overvalued?

Compared to the current market price of 8.46 USD, Amneal Intermediate Inc is Undervalued by 42%.

Back to Top